ReviewThe oncologist2012

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Sai-Hong Ignatius Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.